December 19, 2024
Headlines

CANADA

Strathcona Resources and Canada Growth Fund Forge $2 Billion Partnership for Carbon Capture Innovation

Editor04 mins

Strathcona Resources Ltd. (TSX: SCR) has announced a groundbreaking partnership with Canada Growth Fund (“CGF”), marking a significant leap forward in the realm of carbon capture and sequestration (CCS). Under this strategic agreement, CGF, a prominent $15 billion public investment vehicle, will inject up to $1 billion into CCS infrastructure across Strathcona’s steam-assisted gravity drainage…

Read More

e-Zinc Secures $31 Million to Pioneer Long-Duration Energy Storage Solutions

Editor05 mins

e-Zinc, a trailblazer in sustainable long-duration energy storage utilizing zinc-air battery technology, has announced the successful completion of a $31 million Series A2 funding round. Led by Evok Innovations and bolstered by investments from Mitsubishi Heavy Industries, Export Development Canada (EDC), and Ultratech Capital Partners, this funding will propel e-Zinc’s efforts in advancing commercialization initiatives….

Read More

Rock Tech Secures Up to 100 Million Euros in Grants for Revolutionary Lithium Refinery in Germany

Editor05 mins

Rock Tech Lithium Inc. (TSXV: RCK) (OTCQX: RCKTF) (FWB: RJIB) (WKN: A1XF0V) has announced a significant milestone in its mission to advance sustainable lithium production with the receipt of up to 100 million Euros in grants for its Lithium Converter project in Guben, Germany. The funding, to be provided by the State of Brandenburg and…

Read More

Valneva’s Breakthrough: Canada Approves World’s First Chikungunya Vaccine

Editor02 mins

Valneva SE has achieved a historic milestone with Health Canada’s approval of the world’s first chikungunya vaccine. Following its successful launch in the U.S. and pending European authorization, this decision underscores IXCHIQ®’s pivotal role in global healthcare strategy. Chikungunya, a mosquito-borne virus causing severe joint pain and fever, poses a significant public health threat with…

Read More

Ability Biologics Innovates AI-Driven Antibody Therapeutics with $18 Million Seed Funding Boost

Editor04 mins

Ability Biologics, a trailblazer in AI-driven therapeutic discovery, has closed an $18 million seed funding extension, marking a significant milestone in its quest to revolutionize antibody therapeutics for cancer and immune-related disorders. Led by founding investor Amplitude Ventures, this financing round includes strategic support from Fonds de solidarité FTQ, Investissement Québec, Charles River Laboratories, Theodorus,…

Read More